Dr MBA - Cellectis Chief Officer
| CLLS Stock | USD 2.13 0.01 0.47% |
Insider
Dr MBA is Chief Officer of Cellectis SA
| Age | 47 |
| Address | 8, rue de la Croix Jarry, Paris, France, 75013 |
| Phone | 33 1 81 69 16 00 |
| Web | https://www.cellectis.com |
Cellectis Management Efficiency
The company has return on total asset (ROA) of (0.1609) % which means that it has lost $0.1609 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.822) %, meaning that it created substantial loss on money invested by shareholders. Cellectis' management efficiency ratios could be used to measure how well Cellectis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.32 in 2024. Return On Capital Employed is likely to drop to -0.57 in 2024. At this time, Cellectis' Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 243.1 M in 2024, whereas Total Assets are likely to drop slightly above 270.8 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Todisco | Kymera Therapeutics | 59 | |
| Alessandro MD | Innate Pharma | N/A | |
| MD MBA | Shattuck Labs | 65 | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Michael LaCascia | Foghorn Therapeutics | 59 | |
| Fanny Cavalie | Foghorn Therapeutics | 46 | |
| Michael Wolfe | Kezar Life Sciences | N/A | |
| Ben Strain | Foghorn Therapeutics | N/A | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| Simona King | Passage Bio | 52 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Anish MD | Soleno Therapeutics | 54 | |
| MPH MD | Foghorn Therapeutics | 51 | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
| Gwenn Hansen | Nurix Therapeutics | 53 | |
| Elaine Caughey | Kymera Therapeutics | N/A | |
| Yannis Morel | Innate Pharma | 51 | |
| DVM MBA | Innate Pharma | 58 | |
| Odile Belzunce | Innate Pharma | 44 | |
| Gerald Md | Foghorn Therapeutics | N/A | |
| Peter Rhode | HCW Biologics | 66 | |
Management Performance
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.16 |
Cellectis SA Leadership Team
Elected by the shareholders, the Cellectis' board of directors comprises two types of representatives: Cellectis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cellectis. The board's role is to monitor Cellectis' management team and ensure that shareholders' interests are well served. Cellectis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cellectis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andre Choulika, Chairman of the Board and CEO, Member of the Executive Committee | ||
| MarieBleuenn Terrier, General Counsel, Member of the Executive Committee | ||
| Dr MBA, Chief Officer | ||
| David Sourdive, Co-Founder, Executive VP of Corporate Devel. and Director | ||
| Valerie Cros, Principal Officer | ||
| Kyung NamWortman, Executive Officer | ||
| Philippe Duchateau, Chief Scientific Officer | ||
| Pascalyne Wilson, Director Communications | ||
| Stephan MSc, Chief Officer | ||
| Jean Epinat, Chief Officer | ||
| MSc MSc, Chief Officer | ||
| Arthur Stril, Interim Officer |
Cellectis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cellectis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (2.34) % | ||||
| Operating Margin | (0.60) % | ||||
| Current Valuation | 33.49 M | ||||
| Shares Outstanding | 100.09 M | ||||
| Shares Owned By Insiders | 3.86 % | ||||
| Shares Owned By Institutions | 14.76 % | ||||
| Number Of Shares Shorted | 140.46 K | ||||
| Price To Earning | (14.84) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.